• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UCB expands biotechnology base in Belgium

UCB expands biotechnology base in Belgium

September 17, 2012
CenterWatch Staff

In line with its strategy, and in preparation for the growing demand for biological medicines, UCB, a biopharma focused on the central nervous system and immune system, has opened its new pilot biotechnology plant at its Braine-L’Alleud site in Belgium.

The 5,100 square meter plant—a pilot facility—will include one hundred employees, most of whom will have received high quality training support. It comprises four bioreactors with a total capacity of 3,200 liters. It will also include multiple fermentation reactors, as well as integrated laboratories and additional infrastructure to house a focused new production team.

The plant will produce cell culture-based therapeutic proteins and is dedicated to accelerating the availability of new biotechnology drugs for severe diseases. The facility will focus on developing UCB’s molecules in the research and clinical trial phases. At the same time, manufacturing processes will be designed and optimized to move from development to full scale industrial production.

 “By reinforcing its presence in biotechnology, UCB is equipping itself for the future,” said Roch Doliveux, CEO of UCB. “Today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline. With this bio pilot plant, we will more rapidly initiate clinical studies of new antibody-based therapeutics that are addressing serious unmet medical needs. ”

The entire biotechnology pilot plant project represents an investment by UCB of more than $85 million, supported by the Walloon region. The new plant is currently undergoing a validation phase, which is being carried out alongside the regulatory authorities, and it will become fully operational during the course of 2013.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing